Conventional SPECT/CT quantification is manual and time intensive—often requiring specialized resources to manage the complexity and potential for error. As a result, quantitative SPECT/CT is rarely used clinically.
The only tool to offer automated, accurate, and reproducible quantification for a range of isotopes, xSPECT Quant™ has paved the way for routine SPECT/CT quantification.
xSPECT Quant uses a 3% National Institute of Standards and Technology (NIST) traceable precision source, which allows you to easily standardize uptake values across different cameras, dose calibrators, and facilities.
Accurate to within 5%1, xSPECT Quant is the industry’s most precise and reproducible SPECT/CT quantitative solution. Available for 99mTc, 123I, 177Lu, 111In, and 131I2 imaging, xSPECT Quant enables clinical SPECT/CT quantification to more precisely detect disease and better manage therapy.
The absolute quantification capabilities of xSPECT Quant are also a basis for theranostics, the unique approach of combining diagnostics and therapy
What experts say
Defining the quantitative future of SPECT/CT
Read more about how the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland, is using quantitative SPECT/CT imaging as a meaningful tool for determining prompt diagnoses and developing personalized treatment strategies.
Clinical image gallery
123I xSPECT Quant enables standardized quantification for appropriate diagnosis in equivocal motion disorders.
111In xSPECT Quant enables standardized quantification for evaluation of neuroendocrine tumor.
Sequential xSPECT Quant studies following 4 cycles of 177Lu DOTATATE therapy quantifies tumor and renal absorbed to help determine safety and efficacy of radionuclide therapy.
xSPECT Bone and 99mTc-MDP xSPECT Quant demonstrate response to androgen receptor antagonists in bone metastases.
Differentiation of a rib benign lesion from a metastasis using xSPECT Quant
- 58-year-old patient
- Underwent a prostatectomy
- Underwent a 99mTc DPD bone scan as part of the initial staging
xSPECT Quant-based dosimetry following 177Lu PSMA4 therapy in metastatic prostate cancer
- 82-year-old male
- Presented with castration-resistant prostate cancer and multiple skeletal metastases
- Treated with an intravenous infusion of 8.7 GBq of 177Lu PSMA
Written by A. Hans Vija, PhD, Carl von Gall, MD, and Partha Ghosh, MD
Siemens Healthineers Molecular Imaging
1Data on file.
2xSPECT Quant 131I is not yet commercially available in the United States and in some countries. Due to regulatory reasons, its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.
3The statements by Siemens Healthineers' customers described herein are based on results that were achieved in the customer's unique setting. Since there is no "typical" hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption) there can be no guarantee that other customers will achieve the same results.
4177Lu PSMA is not currently recognized by the U.S. Food and Drug Administration (FDA) or other regulatory agencies as being safe and effective. Siemens does not make any claims regarding its use.